BRAF V600 and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation
Ill, C. R.; Marikar, N. C.; Nguyen, V.; Nangia, V.; Darnell, A. M.; Vander Heiden, M. G.; Reigan, P.; Spencer, S. L.
Show abstract
Targeted kinase inhibitors are well known for their promiscuity and off-target effects. Herein, we define an off-target effect in which several clinical BRAFV600 inhibitors, including the widely used dabrafenib and encorafenib, interact directly with GCN2 to activate the Integrated Stress Response and ATF4. Blocking this off-target effect by co-drugging with a GCN2 inhibitor in A375 melanoma cells causes enhancement rather than suppression of cancer cell outgrowth, suggesting that the off-target activation of GCN2 is detrimental to these cells. This result is mirrored in PC9 lung cancer cells treated with erlotinib, an EGFR inhibitor, that shares the same off-target activation of GCN2. Using an in silico kinase inhibitor screen, we identified dozens of FDA-approved drugs that appear to share this off-target activation of GCN2 and ATF4. Thus, GCN2 activation may modulate the therapeutic efficacy of some kinase inhibitors, depending on the cancer context.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures 97%
- The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. 97%
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer 97%
Similar papers in this journal
Similar papers in this journal
- Inducible mismatch repair streamlines forward genetic approaches to target identification of cytotoxic small molecules 96%
- VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation 96%
- Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.